Geetha Duvuru, Lee Scott M, Shah Shivani, Rahman Hafizur M
Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Baylor University and Baylor College of Medicine's Baylor² Medical Track, Waco, TX, USA.
J Nephrol. 2017 Feb;30(1):147-153. doi: 10.1007/s40620-015-0253-6. Epub 2015 Dec 8.
Renal transplantation (RTx) is the modality of choice for ESRD due to ANCA associated vasculitis (AAV). The significance of ANCA positivity (ANCA+) at the time of RTx on recurrent disease is controversial.
We evaluated clinical outcomes and predictors of vasculitis relapse in sixteen transplanted AAV patients who were ANCA+ at RTx at a single University Medical Center. Allograft function, vasculitis relapse, and predictors of vasculitis relapse were assessed using descriptive statistics and logistic regression analysis.
Our cohort had a median age of 64 years, 88 % Caucasians, 63 % males, 50 % PR3+. All patients were in remission at the time of RTx. Twelve received induction therapy and all were on mycophenolate mofetil, prednisone and tacrolimus. The mean (SD) serum creatinine was 1.2 (0.3) mg/dl at 1 year and 1.8 (1.7) mg/dl at last follow up. Six developed vasculitis relapse at post-transplant. All relapses were treated with escalation in immunosuppression. One non-compliant patient suffered graft loss while the remaining patients achieved remission. In adjusted logistic regression analysis, PR3 ANCA+ patients were two times (OR 2.19, p = 0.71) more likely to experience a relapse compared to MPO ANCA+ patients.
This study demonstrates that PR3 ANCA+ patients may be more likely to experience relapse post-transplant. Further investigation of the predictors of vasculitis relapse among AAV patients who are ANCA+ at the time of RTx needs to be pursued.
肾移植(RTx)是抗中性粒细胞胞浆抗体相关血管炎(AAV)所致终末期肾病(ESRD)的首选治疗方式。肾移植时抗中性粒细胞胞浆抗体阳性(ANCA+)对疾病复发的意义存在争议。
我们评估了在一家大学医学中心接受肾移植时ANCA+的16例AAV移植患者的临床结局及血管炎复发的预测因素。采用描述性统计和逻辑回归分析评估移植肾功能、血管炎复发情况及血管炎复发的预测因素。
我们的队列中位年龄为64岁,88%为白种人,63%为男性,50%为蛋白酶3(PR3)阳性。所有患者在肾移植时均处于缓解期。12例接受了诱导治疗,所有患者均服用霉酚酸酯、泼尼松和他克莫司。1年时平均(标准差)血清肌酐为1.2(0.3)mg/dl,末次随访时为1.8(1.7)mg/dl。6例在移植后发生血管炎复发。所有复发均通过加强免疫抑制治疗。1例不依从患者移植肾失功,其余患者病情缓解。在调整后的逻辑回归分析中,PR3 ANCA+患者复发的可能性是髓过氧化物酶(MPO)ANCA+患者的两倍(比值比2.19,p = 0.71)。
本研究表明,PR3 ANCA+患者移植后可能更易复发。需要对肾移植时ANCA+的AAV患者血管炎复发的预测因素进行进一步研究。